| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MDS.1280 |
| P698 | PubMed publication ID | 11835452 |
| P50 | author | Jonathan M. Brotchie | Q55079469 |
| Susan H Fox | Q66933724 | ||
| P2093 | author name string | Mark Kellett | |
| Alan R Crossman | |||
| A Peter Moore | |||
| P2860 | cites work | Validity and reliability of a rating scale for the primary torsion dystonias | Q70045980 |
| Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum | Q72244709 | ||
| Cannabinoid receptor localization in brain | Q24558751 | ||
| Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia | Q28332947 | ||
| Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. | Q33867668 | ||
| Open label evaluation of cannabidiol in dystonic movement disorders | Q34050762 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy | Q36048236 | ||
| Pallidal activity during dystonia: somatosensory reorganisation and changes with severity | Q36319002 | ||
| A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment | Q37585084 | ||
| Nabilone. A preliminary review of its pharmacological properties and therapeutic use. | Q39385189 | ||
| The central neuropharmacology of psychotropic cannabinoids | Q39632100 | ||
| Loss of cannabinoid receptors in the substantia nigra in Huntington's disease. | Q45290294 | ||
| Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide | Q46417383 | ||
| Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus | Q48406027 | ||
| A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia | Q48471518 | ||
| Globus pallidus internus pallidotomy for generalized dystonia | Q48586235 | ||
| Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. | Q48962147 | ||
| Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. | Q49018761 | ||
| Single-Dose Study of Nabilone in Anxious Volunteers | Q51255447 | ||
| A single dose study of nabilone, a synthetic cannabinoid | Q51272228 | ||
| Overactive prefrontal and underactive motor cortical areas in idiopathic dystonia | Q57089254 | ||
| Nabilone: A Pressure-Reducing Synthetic Benzopyran in Open-Angle Glaucoma | Q66987168 | ||
| Physiologic disposition of nabilone, a cannabinol derivative, in man | Q67585410 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| cannabinoid receptor | Q421237 | ||
| cannabinoids | Q422936 | ||
| placebo-controlled trial | Q108853737 | ||
| CNR2 | Q17907844 | ||
| P304 | page(s) | 145-149 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia | |
| P478 | volume | 17 |
| Q47101767 | A Systematic Review of the Effectiveness of Medical Cannabis for Psychiatric, Movement and Neurodegenerative Disorders |
| Q33244571 | A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force |
| Q34704890 | Cannabinoid-based medicines for neurological disorders--clinical evidence |
| Q37734568 | Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. |
| Q38522769 | Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia |
| Q40701861 | Cannabinoids for the Treatment of Movement Disorders. |
| Q24633884 | Cannabinoids in health and disease |
| Q34549222 | Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options |
| Q27336419 | Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics |
| Q42844506 | Effects of cannabinoid CB1 receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys |
| Q31069022 | Efficacy of pharmacological treatment of dystonia: evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options |
| Q64781374 | Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms? |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q34449698 | Medical marijuana in neurology |
| Q59477201 | Medical treatment of dystonia |
| Q34185013 | Pharmacokinetics and pharmacodynamics of cannabinoids |
| Q34417710 | Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology |
| Q35876026 | The endocannabinoid system and its therapeutic exploitation |
| Q37394164 | The endocannabinoid system as a target for the treatment of motor dysfunction |
| Q24648473 | The endocannabinoid system as an emerging target of pharmacotherapy |
| Q35171113 | The therapeutic potential of cannabinoids for movement disorders |
| Q33964721 | Therapeutic potential of cannabinoids in CNS disease |
| Q34087402 | Treatment strategies for dystonia |
| Q51993486 | [The endogenous cannabinoid system. Therapeutic implications for neurologic and psychiatric disorders]. |
| Q53854698 | [Therapeutic use of cannabinoids in neurology]. |
Search more.